Abstract: The present invention relates to a pharmaceutical combination, the pharmaceutical combination comprising a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic label thereof, a crystal form thereof, a hydrate, a solvate, a diastereomer or enantiomer, and a K-ATP channel blocker. The present invention further relates to a pharmaceutical composition, a fixed dose compound preparation, and a method for preparing the pharmaceutical composition and the fixed dose compound preparation as well as a use thereof.

Abstract: Disclosed herein are pharmaceutical compositions having a mixture of at least one active agent and an ion exchange resin, such that the composition releases about 75% or more of the at least one active agent within about 1 hour as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at about 50 rpm in about 900 ml 0.1N HCl at about 37° C. and related methods. Also disclosed herein are pharmaceutical compositions having a mixture of a drug susceptible to abuse, a non-opioid analgesic and an ion exchange resin, the composition further including at least one gelling agent and related methods.

Abstract: The present disclosure concerns a deodorant emulsion for an aerosol spray which is free from aluminum salts and ethanol, comprising: at least one emulsifier, at least one salt, water, at least one silicone oil and at least one further oil, and a deodorant aerosol spray product comprising a pressure or pump spray container with spray head, the filling of which comprises the deodorant emulsion and optionally a propellant and/or further solvent, and a use of the deodorant aerosol spray product for deodorizing human skin.

Abstract: The present invention provides novel, solid or liquid pharmaceutical preparations comprising a basic or neutral, low molecular weight active pharmaceutical ingredient and the polymer Eudragit® EPO, optionally together with additional pharmaceutically acceptable excipients. The present preparations are for oral or topical administration.

Abstract: A thin film composite gas separation membrane comprising a polyether block amide copolymer coating layer and a nanoporous asymmetric support membrane with nanopores on the skin layer surface of the support membrane and gelatin polymers inside the nanopores on the skin layer surface of the support membrane. A method for making the thin film composite gas separation membrane is provided as well as the use of the membrane for a variety of separations such as separations of hydrogen sulfide and carbon dioxide from natural gas, carbon dioxide removal from flue gas, fuel gas conditioning, hydrogen/methane, polar molecules, and ammonia mixtures with methane, nitrogen or hydrogen and other light gases separations, but also for natural gas liquids recovery and hydrogen sulfide and carbon dioxide removal from natural gas in a single step.

Abstract: Disclosed are composite materials and methods of making them. The composite materials comprise a support member and a cross-linked gel, wherein the cross-linked gel is a polymer synthesized by thiol-ene or thiol-yne polymerization and cross-linking. The cross-linked gel may be functionalized by a thiol-ene or thiol-yne grafting reaction, either simultaneously with the polymerization or as the second step in a two-step procedure. The composite materials are useful as chromatographic separation media.

Abstract: Polymer particle embolics and methods of making same are described. The particle embolics can be used as embolization agents.

Abstract: An object of the present invention is to provide an excellent binder agent composition solving problems such as the decrease in a charge/discharge capacity that occurs in a case where a silicon-containing active material is used, a slurry composition and an electrode in which the binder agent composition is used, and a method for preparing the electrode.

Abstract: Multilayer dissolvable film suitable for oral administration, as well as method of use thereof and method of manufacturing thereof. The dissolvable film contains multiple (e.g., two or more) layers, configured such that the active ingredient(s) can be present in a total amount of at least about 30 wt. % (e.g., at least about 250 mg). The dissolvable film is mucoadhesive and capable of dissolving within about 60 seconds when placed in the oral cavity.

Abstract: A composition and method for the administration of therapeutic and/or diagnostic agents is provided. Specifically, a hybrid system, composed of polymer that harbors drug-loaded lipid nanoparticles, and use thereof for the administration of active agents e.g., anti-cancer agents, is provided.

Abstract: The present disclosure relates to a biocompatible, electrically conductive polymer capable of carrying the electrical potential of a cardiac impulse. The present disclosure also relates to treatments using the electrically conductive polymer, such as for atrial fibrillation.

Abstract: Disclosed herein are nanoparticle compositions and methods of use such as for chemoprevention of cancer, for example oral squamous cell carcinoma (OSCC). The nanoparticle composition comprises a Janus particle comprising at least two chemopreventive agents, wherein at least one of the chemopreventive agents is selected from freeze-dried black raspberries (BRB), a synthetic vitamin A analogue, N-acetylcysteine (NAC), and an anti-interleukin 6 agent. Methods for improving oral health comprising administering to a subject the nanoparticle compositions are also disclosed.

Abstract: Shape memory polymer (SMP) epoxies and composites, and methods of manufacturing the same, are provided. A three-dimensional (3D) printing technique can be used to fabricate a pure thermoset SMP epoxy. A cryogenic sprayer assisted extrusion type 3D printing method can be used to print SMP epoxies and composites of an SMP epoxy and a nanomaterial additive, such as graphene nanoplatelets (GNP).

Abstract: Disclosed are composite materials and methods of making them. The composite materials comprise a support member and a cross-linked gel, wherein the cross-linked gel is a polymer synthesized by thiol-ene or thiol-yne polymerization and cross-linking. The cross-linked gel may be functionalized by a thiol-ene or thiol-yne grafting reaction, either simultaneously with the polymerization or as the second step in a two-step procedure. The composite materials are useful as chromatographic separation media.

Abstract: Microbiota restoration therapy (MRT) compositions (e.g., oral MRT compositions) and methods for manufacturing MRT compositions are disclosed. An example method for manufacturing an MRT composition may include collecting a stool sample, purifying the stool sample to form a purified sample, stabilizing the purified sample to form a stabilized sample, converting the stabilized sample to a solid, adding one or more additives and/or excipients to the solid to form a treatment composition, and encapsulating the treatment composition.

Abstract: A screw-shaped anchoring fixture for anchoring a prosthesis in the skull bone. The anchoring fixture comprises a main body configured to be implanted into the bone and a flange configured to function as a stop to prevent the main body from completely penetrating through the bone. The main body comprises a distal tapered apical portion, a first portion, and a second portion. The inner diameter of the second portion is greater than the inner diameter of the first portion. The method for inserting the anchoring fixture includes providing the anchoring fixture, drilling a hole, and inserting the anchoring fixture into the hole until the flange contacts the skull bone, wherein the hole has a diameter that is greater than the inner diameter of the first portion and less than the outer diameter of the second portion.

Abstract: The present invention relates to an improved active or inactive pharmaceutical ingredient-polymer composition and process of preparation thereof. In particular, the present invention relates to an improved active or inactive pharmaceutical ingredient-polymer composition and process of preparation thereof wherein the monomer encapsulates particles of active or inactive pharmaceutical ingredient at molecular level and with controlled polymerization process the monomer turns into the said polymer coat over the said active or inactive pharmaceutical ingredient that facilitates the disclosed invention to be completed a single step process.

Abstract: An organic/inorganic composite hydrogel can be prepared only through mixing at a room temperature and that has high modulus of elasticity and a self-supporting property that allows a shape to be maintained in water, and a method produces the hydrogel. A hydrogel forming composition that is capable of forming a hydrogel having a self-supporting property, includes: a water-soluble organic polymer having an organic acid structure, an organic acid salt structure, or an organic acid anion structure; a silicate salt; a dispersant for the silicate salt; and a compound having or generating divalent or higher valent positive charge; a hydrogel formed of the composition, and a method for producing the hydrogel.

Abstract: Provided is a method of suspension polymerization comprising (I) providing a composition comprising droplets distributed in an aqueous medium, wherein the droplets comprise one or more boronic acids, one or more monomers, and one or more initiators, and wherein the aqueous medium comprises polyvinyl alcohol; wherein the one or more boronic acids are present in an amount of 0.002% or more, by weight based on the weight of the droplets, and (II) stressing the composition so that the initiator initiates polymerization of the monomer.

Abstract: A method of treating a subterranean formation including suspending proppant particulates in a treatment fluid, wherein the proppant particles include a coating comprising a salt-tolerant, water-swellable polymer, and the treatment fluid includes at least one fluid consisting of fresh water, salt water, seawater, brine, an aqueous salt solution, and combinations thereof; and introducing the treatment fluid containing the settling retardant proppant particulates into the subterranean formation. A composite proppant particle includes a proppant substrate and a salt tolerant polymeric layer deposited on the proppant substrate.

Abstract: A method for preparing a composition for external treatment of wounds includes charging at least 90% of the oxygen binding sites of hemoglobin with carbon monoxide during or after isolation from its natural environment. The method further includes adding at least one further ingredient selected from the group consisting of electrolyte(s), preservative(s), stabilizer(s), anti-flocculant(s), anticoagulant(s), pH buffering agent(s), solvent(s), antioxidant(s), film-forming agent(s) and crosslinking agent(s). The method can further include packaging the composition, such as in an aerosol can.

Abstract: Disclosed are composite materials and methods of making them. The composite materials comprise a support member and a cross-linked gel, wherein the cross-linked gel is a polymer synthesized by thiol-ene or thiol-yne polymerization and cross-linking. The cross-linked gel may be functionalized by a thiol-ene or thiol-yne grafting reaction, either simultaneously with the polymerization or as the second step in a two-step procedure. The composite materials are useful as chromatographic separation media.

Abstract: The invention relates to a transdermal therapeutic system, comprising a back layer that is impermeable to an active ingredient, a polymer matrix containing the active ingredient, and a protective layer that can be pulled off, wherein 5-aminolevulinic acid hydrochloride is used as the active ingredient and the basic polymer of the polymer matrix is an adhesive polyacrylate. Said transdermal therapeutic system is suitable for diagnosing and treating preliminary stages of skin cancer, such as actinic keratosis, and oncological skin diseases.

Abstract: A composition containing biocompatible hydrogel encapsulating mammalian cells and anti-inflammatory drugs is disclosed. The encapsulated cells have reduced fibrotic overgrowth after implantation in a subject. The compositions contain a biocompatible hydrogel having encapsulated therein mammalian cells and anti-inflammatory drugs or polymeric particles loaded with anti-inflammatory drugs. The anti-inflammatory drugs are released from the composition after transplantation in an amount effective to inhibit fibrosis of the composition for at least ten days. Methods for identifying and selecting suitable anti-inflammatory drug-loaded particles to prevent fibrosis of encapsulated cells are also described. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.

Abstract: A timed release pharmaceutical composition comprising donepezil is provided, wherein the composition exhibits the in vitro dissolution profile when tested in a Paddle dissolution apparatus at 50 rpm in 900 ml 6.8 buffer at 37° C., less than about 20% w/w of donepezil is released in 3 to 6 hrs, and more than 90% w/w of donepezil is released after 12 hrs.

Abstract: An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.

Abstract: An aqueous fluid, possibly a wellbore fracturing fluid, comprises an aqueous solution or dispersion of a first polymer, which may be polysaccharide, as a thickener and a cross linking agent to enhance the viscosity of the fluid by crosslinking the first polymer, wherein the crosslinking agent is a second polymer comprising at least one polymer chain with phenyl boronate groups distributed along the polymer chain and the phenyl boronic acid groups have nitrogen attached to the phenyl group at a position which is meta relative to the boronate group.

Abstract: A powdery or granulated composition, containing: (a) a copolymer containing, in polymerized form, a C1- to C4-alkyl ester of acrylic or methacrylic acid and an alkyl(meth)acrylate monomer containing a tertiary amino group in an alkyl radical; (b) 0.5 to 10% by weight based on (a) of a dicarboxylic acid having 3 to 10 carbon atoms; and (c) 5 to 20% by weight based on (a) of a fatty monocarboxylic acid having 8 to 18 carbon atoms, where the composition contains at least by 30% by weight of (a), (b), and (c).

Abstract: Described herein are stable orally disintegrating tablets containing a proton pump inhibitor, methods for making the same, and methods for treating subjects in need thereof. In particular, the orally disintegrating tablets are composed of a plurality of coated units admixed with a disintegrant that demonstrate decreased friability and increased hardness.

Abstract: A bone void filler material is provided that is configured for sustained release of a therapeutic agent. The bone void filler material comprises a biodegradable matrix having ceramic particles and cement beads disposed within the matrix, the cement beads loaded with the therapeutic agent to cause sustained release of the therapeutic agent. Methods of use are also disclosed.

Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.

Abstract: An object of the present invention to provide an antiadhesive material designed to have time-varying fluidity as it exhibits a gel form of high fluidity at the time of administration, and exhibits a gel form of low fluidity after it is administered to an incised and sutured site. A powdery antiadhesive material to be mixed with an aqueous solvent upon use containing alginic acid and/or a salt thereof, that is configured to be mixed with the aqueous solvent upon use so that the viscosity at 37° C. is less than or equal to 70 mPas·s at the time of 5 minutes after mixing with the aqueous solvent, and the viscosity at 37° C. is more than or equal to 120 mPas·s at the time of 60 minutes after mixing, will have high fluidity at the time of administration when it is mixed with an aqueous solvent upon use in a clinical scene, and have low fluidity after it is administered to an incised and sutured site, and thus is capable of satisfying both the excellent operability and the antiadhesive effect.

Abstract: The invention relates to a novel antibiotic delivery vehicle for impregnating bone cement wherein said vehicle is an antibiotic encapsulated liposome having a block co-polymer on its surface; a method for the manufacture of a bone cement impregnated with antibiotic or a mixture of antibiotics using said vehicle; and also a novel bone cement made therewith and/or thereby.

Abstract: A composition containing biocompatible hydrogel encapsulating mammalian cells and anti-inflammatory drugs is disclosed. The encapsulated cells have reduced fibrotic overgrowth after implantation in a subject. The compositions contain a biocompatible hydrogel having encapsulated therein mammalian cells and anti-inflammatory drugs or polymeric particles loaded with anti-inflammatory drugs. The anti-inflammatory drugs are released from the composition after transplantation in an amount effective to inhibit fibrosis of the composition for at least ten days. Methods for identifying and selecting suitable anti-inflammatory drug-loaded particles to prevent fibrosis of encapsulated cells are also described. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.

Abstract: A screw-shaped anchoring fixture for anchoring a prosthesis in the skull bone. The anchoring fixture comprises a main body configured to be implanted into the bone and a flange configured to function as a stop to prevent the main body from completely penetrating through the bone. The main body comprises a distal tapered apical portion, a first portion, and a second portion. The inner diameter of the second portion is greater than the inner diameter of the first portion. The method for inserting the anchoring fixture includes providing the anchoring fixture, drilling a hole, and inserting the anchoring fixture into the hole until the flange contacts the skull bone, wherein the hole has a diameter that is greater than the inner diameter of the first portion and less than the outer diameter of the second portion.

Abstract: Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix which includes the propynylaminoindan, a pressure sensitive adhesive that includes an acrylate copolymer and a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.

Abstract: The present invention provides a means for improving water-solubility of polysaccharide. A polysaccharide powder according to the present invention has a particle size distribution in which 30 vol % or more of the total volume of the powder has particle sizes of 200 to 750 ?m.

Abstract: Methods and apparatus for the in vitro modelling of changes that occur on administration of a drug formulation are described, in particular for studying the changes that take place on administration of protein or peptide drug formulations by subcutaneous injection.

Abstract: An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.

Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals. This invention provides hydrogels that degrade to smaller, soluble components in a non-enzymatic process upon exposure to physiological conditions and to methods to prepare them. The hydrogels are prepared from crosslinking agents that undergo elimination reactions under physiological conditions, thus cleaving the crosslinking agent from the backbone of the hydrogel. The invention also relates to the crosslinking agents themselves and intermediates in forming the hydro gels of the invention. The biodegradable hydro gels prepared according to the methods of the invention may be of use in diverse fields, including biomedical engineering, absorbent materials, and as carriers for drug delivery.

Abstract: The present invention relates to chitosan hydrogel microparticles of a median size d50 comprised between 1 and 500 ?m (obtained from a number distribution), the chitosan having a degree of acetylation of less than equal to 20% and its concentration in the hydrogel being comprised between 0.25 and 5% by weight based on a total weight of the hydrogel, for use in neuron regeneration and/or in the repair of the nervous system, advantageously of the central nervous system, and/or in the grafting of neurons and/or in the treatment of neurodegenerative diseases and/or in the treatment of paralyses. It also relates to an implant comprising an aqueous suspension of microparticles mixed with Schwann cells and/or stem cells and/or trophic factors.

Abstract: Methods and materials relating to a medicament preparation comprising a curcuminoid component and a euradit component provided as a curcuminoid-eudragit complex, which enhance the bioavailability of the curcumin component and are useful for the treatment of various diseases including cancer, neurodegeneration, inflammation, and immunodeficiency. In some aspects, the curcuminoid component comprises curcumin to prepare a curcumin-eudragit complex and a medicament comprising curcumin-eudragit complexes.

Abstract: Water soluble biodegradable polymers were prepared by an organoacid catalyzed ring opening polymerization (ROP) of a cyclic carbonate monomer bearing an active ester side chain. The initial polymer comprising an active ester side chain was treated with an amino-alcohol, which transformed the active ester groups to N-substituted amide groups bearing mono-hydroxy alkyl groups and/or dihydroxy alkyl groups, thereby forming the water soluble polymers. The water-soluble polymers are non-toxic and exhibit stealth properties in buffered serum solution.

Abstract: The present disclosure provides novel formulations suitable for the intravaginal delivery of tinidazole, as well as methods of using the same.

Abstract: A composition includes a responsive block copolymer, the responsive block copolymer including at least one block A that is a triggerable copolymer, the triggerable copolymer including at least one lower critical solution temperature monomer and at least one charged monomer, wherein the triggerable copolymer block A is a dual trigger block configured to trigger on temperature and ionic strength, and wherein the responsive block copolymer micellizes or gels at a temperature between 28° C. and 37° C. and a salt concentration of about 0.9 wt %.

Abstract: A herbal composition for wound healing is disclosed. The herbal composition comprises an extract of honeysuckle and an extract of mint in a weight ration of 1:2 to 2:1. The herbal composition further comprises a medical acceptable excipient.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: The invention relates to a dental restorative material on the basis of at least one compound of Formula I A-[X-Q-(Y-CG)n]m?? Formula I, wherein CG represents in each case independently an azide group N3 or an alkyne group selected from the group consisting of —CR1R2—C?CH, with the proviso that the dental restorative material comprises at least one compound of Formula I comprising an azide group and at least one compound of Formula I comprising an alkyne group. The invention also relates to the use of the dental restorative materials according to the invention for preparing dental composites, preferably composite blanks, which are suitable in particular for mechanical processing by means of computer-aided processing techniques such as milling and grinding processes, and which are suitable above all for preparing dental restoration materials such as inlays, onlays, crowns, bridges or veneering materials.

Abstract: The present invention provides a process for converting a solid (meth)acrylate copolymer into a dispersed form by preparing an aqueous dispersion comprising the components (a) a (meth)acrylate copolymer which is composed of free-radical polymerized methyl methacrylate, ethylacrylate and a salt of 2-trimethylammoniumethyl methacrylate, present in solid form as a powder or as a granulate, (b) up to 50% by weight calculated on the (meth)acrylate copolymer (a) of a dispersing agent selected from the groups of (b) i) plasticizers in combination with emulsifiers and/or (b) ii) pharmaceutically acceptable carbohydrates having 6 to 18 carbon atoms with a functional group and (c) water by mixing the components (a), (b) and (c) to give a suspension which becomes an aqueous dispersion during the conversion of the solid (meth)acrylate copolymer into the dispersed form, characterized in that, the (meth)acrylate copolymer is converted into the dispersed form by means of the presence of the dispersing agent at a temperature

Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.